A study of nearly 1000 patients with HCC found that black patients with the disease had a 33% greater risk of death compared with non-Hispanic whites.
A potential link between long-term oral treatment with nucleos(t)ide analogues for chronic hepatitis B virus (HBV) and an increased risk of colorectal and cervical cancers was demonstrated.
Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.
Chemotherapy or immunosuppressive treatment may reactive hepatitis B virus in patients previously infected with the virus.
Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma (HCC).
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|